<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="367920">
  <stage>Registered</stage>
  <submitdate>7/02/2015</submitdate>
  <approvaldate>1/04/2015</approvaldate>
  <actrnumber>ACTRN12615000304538</actrnumber>
  <trial_identification>
    <studytitle>A Pharmacokinetic and Safety Study of the Chrono  Nicotine Replacement Therapy System in male smokers.</studytitle>
    <scientifictitle>A pharmacokinetic and safety study of the Chrono Nicotine Replacement Therapy System in male smokers.
</scientifictitle>
    <utrn>U1111-1167-0349</utrn>
    <trialacronym />
    <secondaryid>PK2014-001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>cigarette addiction</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Addiction</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Nicotine Replacement Therapy System
6 doses of 6% nicotine formulation over 24 hours.  Doses delivered at T0, T1, T6, T7, T12, T13
transdermally administered using the Chrono IDC 5 device through a patch.  Pharmacokinetic analysis and skin tolerability using a 7 point visual scale will be used.</interventions>
    <comparator>no comparator</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>PK analysis with blood samples</outcome>
      <timepoint>PK analysis over 30 hours:
blood draws at T= 0, 15 min for 3 hours, every hour through hour 16 then every 2 hours through hour 30.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Safety assessment with standard Adverse event evaluation and visual skin irritation and tolerability assessments at T0, T1, T6, T7, T12 T13 and T24 and T30 hours.</outcome>
      <timepoint>Safety assessments at T0, 1, 6, 7, 12, 13, 24 and 30 hours by verbal and visual assessments</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Skin irritation from device/drug placement and drug delivery. Skin irritation is evaluated with a 7 point visual scale.</outcome>
      <timepoint>Over T=0, 1, 6, 7, 12, 13, 24 and 30 hours, the evaluation will be conducted.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>smokers
caucasians
male</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>50</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>infections
opiate use
consume more than 2 alcoholic beverages a day
skin tattoos
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>Screening visit</concealment>
    <sequence>no randomisation</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Pharmacokinetics</endpoint>
    <statisticalmethods>descriptive statistics </statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>16/02/2015</anticipatedstartdate>
    <actualstartdate>16/02/2015</actualstartdate>
    <anticipatedenddate>17/02/2015</anticipatedenddate>
    <actualenddate>17/02/2015</actualenddate>
    <samplesize>12</samplesize>
    <actualsamplesize>12</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <postcode>3004 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Chrono Therapeutics Australia PTY LTD</primarysponsorname>
    <primarysponsoraddress>C/-MPR Group PTY LTD
Floor 19, HWT Tower
40 City Road
Southbank
Victoria 3004</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Chrono Therapeutics Australia PTY LTD</fundingname>
      <fundingaddress>C/-MPR Group PTY LTD
Floor 19, HWT Tower
40 City Road
Southbank
Victoria 3004</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Nucleus Network Limited (Trading as Centre for Clinical Studies)</sponsorname>
      <sponsoraddress>5th Floor Burnet Tower, 89 Commercial Road, Melbourne
Victoria 3004</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Phase 1 PK study with Descriptive statistics for Chrono Nicotine Replacement Therapy System (IDC-5)
Including assessment of general safety</summary>
    <trialwebsite>none</trialwebsite>
    <publication>none</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Alfred Ethics Committee</ethicname>
      <ethicaddress>Commercial Road
Melbourne, Victoria 3004</ethicaddress>
      <ethicapprovaldate>3/02/2015</ethicapprovaldate>
      <hrec>12/15</hrec>
      <ethicsubmitdate>22/01/2015</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Michael Araco</name>
      <address>Nucleus Network
5th Floor Burnet Tower 
89 Commercial Road
Melbourne Victoria 3004</address>
      <phone>+61 (3) 9076 8900</phone>
      <fax>+61 3 9076 8911</fax>
      <email>M.Araco@nucleusnetwork.com.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Mr</title>
      <name>Cameron Johnson</name>
      <address>Nucleus Network
5th Floor Burnet Tower
89 Commercial Road
Melbourne Victoria 3004</address>
      <phone>+61 3 9076 8900</phone>
      <fax>+61 3 9076 8911</fax>
      <email>C.Johnson@nucleusnetwork.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Patti Oto</name>
      <address>Chrono Therapeutics Australia PTY LTD
3953 Eden Way
Hayward CA 94545, USA</address>
      <phone>+1-925-286-6991</phone>
      <fax>none</fax>
      <email>poto@chronothera.com</email>
      <country>United States of America</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Patti Oto</name>
      <address>3953 Eden Way
Hayward, CA 94545, USA</address>
      <phone>1-925-286-6992</phone>
      <fax>none</fax>
      <email>poto@chronothera.com</email>
      <country>United States of America</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>